BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 12792514)

  • 21. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.
    White CA; Cross SM; Kurilla MG; Kerr BM; Schmidt C; Misko IS; Khanna R; Moss DJ
    Virology; 1996 May; 219(2):489-92. PubMed ID: 8638417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
    Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.
    Gandhi MK; Wilkie GM; Dua U; Mollee PN; Grimmett K; Williams T; Whitaker N; Gill D; Crawford DH
    Am J Transplant; 2007 May; 7(5):1293-9. PubMed ID: 17425621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
    Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder.
    Khatri VP; Baiocchi RA; Peng R; Oberkircher AR; Dolce JM; Ward PM; Herzig GP; Caligiuri MA
    J Immunol; 1999 Jul; 163(1):500-6. PubMed ID: 10384154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
    Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
    Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease.
    McAulay KA; Haque T; Urquhart G; Bellamy C; Guiretti D; Crawford DH
    J Immunol; 2009 Mar; 182(6):3892-901. PubMed ID: 19265169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection].
    Babel N; Hammer MH; Reinke P
    Dtsch Med Wochenschr; 2003 Mar; 128(11):548-50. PubMed ID: 12635027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of cytotoxic T lymphocytes for immunotherapy of EBV-associated malignancies.
    Smith C; Khanna R
    Methods Mol Biol; 2010; 651():49-59. PubMed ID: 20686959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.